---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091006"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:18:09.520836+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23

## Summary
- Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.
- Cash $5.2M at June 30, 2023, down from $19.9M at Dec 31, 2022; cash runway into Q4 2023.
- WM CLOVER-WaM pivotal top-line data expected 2H23; NDA and 2024 product launch on target.
- Phase 1b in pediatric high-grade gliomas to start Q3 2023; CNSL cohort expanded after complete response.
- Multiple myeloma data: 40-62% response rates in triple-class refractory and post-BCMA patients.

## SEC filing metadata
- accession: 0001104659-23-091006
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/0001104659-23-091006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/tm2323620d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091006
- JSON: https://secwatch.observer/filing/0001104659-23-091006.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091006.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income ($8.2) million, or ($0.73) per share, EPS ($0.73) per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: ($8.2) million, or ($0.73) per share
  - EPS: ($0.73) per share
  - Result: reported results
  source text: The net loss attributable to common stockholders for the three months ended June 30, 2023 was ($8.2) million, or ($0.73) per share, compared to ($7.4) million, or ($1.22) per share, for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/0001104659-23-091006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.